DOCSLIB.ORG

Series Editors Ronald J. Bradley R. Adron Harris

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Series Editors Ronald J. Bradley R. Adron Harris SERIES EDITORS RONALD J. BRADLEY Departmentof Psychiatry, Collegeof Medicine The University of Tennessee Health Science Center Memphis,Tennessee, USA R. ADRON HARRIS Waggoner Centerfor Alcoholand Drug Addiction Research The University of Texas at Austin Austin,Texas, USA PETER JENNER Division of Pharmacologyand Therapeutics GKTSchoolof Biomedical Sciences King’s College, London, UK EDITORIAL BOARD ERIC AAMODT HUDA AKIL PHILIPPE ASCHER MATTHEW J. DURING DONARD S. DWYER DAVID FINK MARTIN GIURFA BARRY HALLIWELL PAUL GREENGARD JON KAAS NOBU HATTORI LEAH KRUBITZER DARCY KELLEY KEVIN MCNAUGHT BEAU LOTTO JOS�E A. OBESO MICAELA MORELLI CATHY J. PRICE JUDITH PRATT SOLOMON H. SNYDER EVAN SNYDER STEPHEN G. WAXMAN JOHN WADDINGTON Pharmacology of 5-HT6 Receptors-Part 1 EDITED BY FRANCO BORSINI Sigma-Tau Industrie Farmaceutiche Riunite S.P.A., Pomezia, Italy AMSTERDAM • BOSTON • HEIDELBERG • LONDON NEW YORK • OXFORD • PARIS • SAN DIEGO SAN FRANCISCO • SINGAPORE • SYDNEY • TOKYO Academic Press is an imprint of Elsevier Academic Press is an imprint of Elsevier 360 Park Avenue South, New York, NY 10010-1700 525 B Street, Suite 1900, San Diego, California 92101-4495, USA 32 Jamestown Road, London NW1 7BY, UK This book is printed on acid-free paper. Copyright © 2010, Elsevier Inc. All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means electronic, mechanical, photocopying, recording or otherwise without the prior written permission of the publisher. The appearance of the code at the bottom of the first page of a chapter in this book indicates the Publisher’s consent that copies of the chapter may be made for personal or internal use of specific clients. This consent is given on the condition, however, that the copier pay the stated per copy fee through the Copyright Clearance Center, Inc. (www.copyright.com), for copying beyond that permitted by Sections 107 or 108 of the U.S. Copyright Law. This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale. Copy fees for pre-2007 chapters are as shown on the title pages. If no fee code appears on the title page, the copy fee is the same as for current chapters. 0074-7742/2007 $35.00 Permissions may be sought directly from Elsevier’s Science & Technology Rights Department in Oxford, UK: phone: (þ44) 1865 843830, fax: (þ44) 1865 853333, E-mail: [email protected]. You may also complete your request on-line via the Elsevier homepage (http://elsevier.com), by selecting ‘‘Support & Contact’’ then ‘‘Copyright and Permission’’ and then ‘‘Obtaining Permissions.’’ For information on all Elsevier publications visit our website at books.elsevier.com ISBN: 978-0-12-384976-2 PRINTED AND BOUND IN THE UNITED STATES OF AMERICA 10111213 987654321 Working together to grow libraries in developing countries www.elsevier.com | www.bookaid.org | www.sabre.org CONTRIBUTORS Numbers in parentheses indicate the pages on which the authors contributions begin. Paola Bonsi (111), Laboratory of Neurophysiology and Plasticity, I.R.C.C.S. Fondazione Santa Lucia, Rome, Italy Javier Burguen˜o (89), Drug Discovery & Preclinical Development, ESTEVE, Barcelona, Spain Annamaria Cattaneo (129), Division of Biology and Genetics, Department of Biomedical Sciences and Biotechnology, University of Brescia, Brescia, Italy Xavier Codony (89), Drug Discovery & Preclinical Development, ESTEVE, Barcelona, Spain Massimo Gennarelli (129), Division of Biology and Genetics, Department of Biomedical Sciences and Biotechnology and Head of the Genetics Unit, UniversityofBrescia,IRCCS SanGiovannidiDio,Fatebenefratelli, Brescia, Italy Kevin G. Liu (1), Lundbeck Research USA, Paramus, NJ 07652, USA Angelo Mancinelli (153), Sigma-tau Industrie Farmaceutiche Riunite S.P.A., Pomezia, Rome, Italy Graziella Madeo (111), Department of Neuroscience, University Tor Vergata, Rome, Italy Gloria Oranias Olsina (35), Intellectual Property Department, ESTEVE, Barcelona, Spain Antonio Pisani (111), Laboratory of Neurophysiology and Plasticity, I.R.C.C. S. Fondazione Santa Lucia, Rome, Italy and Department of Neuroscience, University Tor Vergata, Rome, Italy Maria Javier Ram�ırez (89), Pharmacology Department, University of Navarra, Pamplona, Spain Teresa Riccioni (67), Sigma-tau Industrie Riunite S.P.A., Pomezia (Roma), Italy Albert J. Robichaud (1), Lundbeck Research USA, Paramus, NJ 07652, USA Giuseppe Sciamanna (111), Laboratory of Neurophysiology and Plasticity, I. R.C.C.S. Fondazione Santa Lucia, Rome, Italy ix x CONTRIBUTORS Annalisa Tassone (111), Laboratory of Neurophysiology and Plasticity, I.R.C. C.S. Fondazione Santa Lucia, Rome, Italy Jose� Miguel Vela (89), Drug Discovery & Preclinical Development, ESTEVE, Barcelona, Spain Nicolas Vincent Ruiz (35), Intellectual Property Department, ESTEVE, Barcelona, Spain PREFACE The field of 5-HT6 receptors is quite recent story. The number of patents (Ruiz and Oranias, this book) and scientific publications is increasing every year. If one considers the very first indication of the probable presence of 5-HT6 receptors in 1979 (MacDermont et al., 1979), until 1998, only 33 scientific communications were published in this 19-year period, mainly focused on distribution, structure, and gross function of the receptor. Pharmaceutical companies found potentially interesting the interference with the function of this receptor and started to synthesize various 5-HT6 receptor ligands (Liu and Robichaud, this book). Between 1999 and 2004, in 5 years, the number of publications raised to 79. After the first period, with the advent of several 5-HT6 ligands, the number of publications increased even more and, between 2005 and mid-2010, reached 154. With the rise of the number of researchers working in this field and then with the increase of different experimental settings, the information on 5-HT6 recep­ tors started to appear inconsistent. In fact, the definition of 5-HT6 receptor agonist or antagonist may be test dependent (Codony et al., this book), and this may explain why both agonists and antagonists may exert similar pharmacolo­ gical effects (part two of this book). Also the first enthusiasm in going to clinical phase with 5-HT6 ligands (part two of this book), as antiobese or anti-amnesic agents, was attenuated by the unsatisfactory clinical results. Also the first idea to use 5-HT6 ligands against cognitive impairment associated with schizophrenia seems destined to be unsuccesful (part two of this book). However, so far, no genetic modification has clearly been associated with any pathology (Gennarelli and Cattaneo, this book). In the field of 5-HT6 receptors, neurochemical (part two of this book) and electrophysiological (Tassone et al., this book) properties of the receptor are also far to be clearly understood. Therefore, it is difficult to ascertain 5-HT6 receptor pharmacological effects, since many pieces of information are unsatisfactory, such as pharmacokinetics/metabolism of the 5-HT6 ligands (Mancinelli, this book), or how radioligands bind to the receptor (Riccioni, this book) (Figure 1). This book was thought to summarize all the data so far obtained in order to put forward some hypothesis for the inconsistencies in the 5-HT6 field. One is that 5-HT6 receptors might exist in different conformational states, according to the G protein with which the 5-HT6 receptor interacts. Since the coupling with the various G proteins may depend on cellular environment, which is differently xi xii PREFACE 180 160 140 120 100 80 60 40 20 Number of scientific communications 0 1979–1998 1999–2004 2005–2010 Years FIG. 1. Number of scientific publications in the field of 5-HT6 receptors since the first possible publication. sensitive to various stressors, the final output (agonist versus antagonist) might depend on cellular state itself. If one assumes that the various 5-HT6 receptor ligands might bind to different receptor sites, it might become clearer why similar pharmacological properties are shared by alleged agonists and antagonists. If this hypothesis is confirmed, 5-HT6 receptor might be a type of receptor that is cell- state sensitive. However, there is no clear explanation for the inconsistencies in the 5-HT6 field. This book wants to evidence the state of the art in the field of 5-HT6 receptor physiology and pharmacology. We hope that this book may represent a reference information for all researchers who work in the field of 5-HT6 receptors. The book on “Pharmacology of 5-HT6 receptors” is published in two parts. The first part deals with in-vitro results and pharmakinetics of 5-HT6 receptor ligands, and the second part with in-vivo findings. Reference MacDermont, J., Higashida, H., Wilson, S.P., Matsuzawa, H., Minna, J., and Nirenberg, M. (1979). Adenylate cyclase and acetylcholine release regulated by separate serotonin receptors of somatic cell hybrids. Proc. Natl. Acad. Sci. U. S. A. 76, 1135–1139. FRANCO BORSINI 5-HT6 MEDICINAL CHEMISTRY Kevin G. Liu and Albert J. Robichaud Lundbeck Research USA, Paramus, NJ 07652, USA I. Introduction II. 5-HT6 Antagonists A. Bisaryl Sulfonamides and Sulfones B. Piperazinylbenzenesulfonamides C. Indoles D. Indazoles E. Azaindoles and Azaindazoles F. Benzofuran, Benzothiaphenes, Benzimidazoles, Thienopyrroles, and Pyrazolotriazines G. Quinolines, Isoquinolines, and Naphthalenes H. Benzene and Its Fused Carbocyclic Derivatives I. Miscellaneous Derivatives Lacking
Load more

Recommended publications
  • TABLE 1 Studies of Antagonist Activity in Constitutively Active
    TABLE 1 Studies of antagonist activity in constitutively active receptors systems shown to demonstrate inverse agonism for at least one ligand Targets are natural Gs and constitutively active mutants (CAM) of GPCRs. Of 380 antagonists, 85% of the ligands demonstrate inverse agonism. Receptor Neutral Antagonist Inverse Agonist Reference Human β2-adrenergic Dichloroisoproterenol, pindolol, labetolol, timolol, Chidiac et al., 1996; Azzi et alprenolol, propranolol, ICI 118,551, cyanopindolol al., 2001 Turkey erythrocyte β-adrenergic Propranolol, pindolol Gotze et al., 1994 Human β2-adrenergic (CAM) Propranolol Betaxolol, ICI 118,551, sotalol, timolol Samama et al., 1994; Stevens and Milligan, 1998 Human/guinea pig β1-adrenergic Atenolol, propranolol Mewes et al., 1993 Human β1-adrenergic Carvedilol CGP20712A, metoprolol, bisoprolol Engelhardt et al., 2001 Rat α2D-adrenergic Rauwolscine, yohimbine, WB 4101, idazoxan, Tian et al., 1994 phentolamine, Human α2A-adrenergic Napthazoline, Rauwolscine, idazoxan, altipamezole, levomedetomidine, Jansson et al., 1998; Pauwels MPV-2088 (–)RX811059, RX 831003 et al., 2002 Human α2C-adrenergic RX821002, yohimbine Cayla et al., 1999 Human α2D-adrenergic Prazosin McCune et al., 2000 Rat α2-adrenoceptor MK912 RX821002 Murrin et al., 2000 Porcine α2A adrenoceptor (CAM- Idazoxan Rauwolscine, yohimbine, RX821002, MK912, Wade et al., 2001 T373K) phentolamine Human α2A-adrenoceptor (CAM) Dexefaroxan, (+)RX811059, (–)RX811059, RS15385, yohimbine, Pauwels et al., 2000 atipamezole fluparoxan, WB 4101 Hamster α1B-adrenergic
    [Show full text]
  • WO 2017/145013 Al 31 August 2017 (31.08.2017) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/145013 Al 31 August 2017 (31.08.2017) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 498/04 (2006.01) A61K 31/5365 (2006.01) kind of national protection available): AE, AG, AL, AM, C07D 519/00 (2006.01) A61P 25/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (21) Number: International Application DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/IB20 17/050844 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (22) International Filing Date: KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, 15 February 2017 (15.02.2017) MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (25) Filing Language: English RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (26) Publication Language: English TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 62/298,657 23 February 2016 (23.02.2016) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant: PFIZER INC. [US/US]; 235 East 42nd Street, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, New York, New York 10017 (US).
    [Show full text]
  • New Therapeutic Property of Dimebon As a Neuroprotective Agent
    Send Orders for Reprints to [email protected] Current Medicinal Chemistry, 2016, 23, 1-12 1 REVIEW ARTICLE New Therapeutic Property of Dimebon as a Neuroprotective Agent Aleksey Ustyugov1, Elena Shevtsova1, George E. Barreto2,3, Ghulam Md Ashraf 4, Sergey O. Bachurin1 and Gjumrakch Aliev1,5,6,* 1Institute of Physiologically Active Compounds, Russian Academy of Sciences, Severniy Proezd 1, Cher- nogolovka, 142432, Russia; 2Departamento de Nutrición y Bioquímica, Facultad de Ciencias, Pontificia Uni- versidad Javeriana, Bogotá D.C., Colombia; 3Instituto de Ciencias Biomédicas, Universidad Autónoma de Chile, Santiago, Chile; 4King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Ara- bia; 5GALLY International Biomedical Research Consulting LLC., 7733 Louis Pasteur Drive, #330, San An- tonio, TX, 78229, USA; 6School of Health Science and Healthcare Administration, University of Atlanta, E. Johns Crossing, #175, Johns Creek, GA, 30097, USA Abstract: Dimebon (or Latrepirdine) was initially used as an anti-histamergic drug but later new therapeutic properties were rediscovered, adding to a growing body of “old” agents with prominent neuroprotective effects. In the present manuscript, we are focusing on our latest study on Dimebon with regard to brain’s pathological processes using in vivo protei- A R T I C L E H I S T O R Y nopathy models. In the study, neurodegenerative pathology has been attributed to a group of aggregate-prone proteins: hyperphosphorylated tau, fused in sarcoma and γ-synuclein , which Received: March 13, 2016 Revised: June 08, 2016 are involved in a number of neurological disorders. We have also presented our in vitro Accepted: July 24, 2016 model based on overexpression of an aberrant mutant form of transactive response DNA DOI: 10.2174/0929867323666160804 binding 43 kDa protein in cultured SH-SY5Y neuroblastoma cells.
    [Show full text]
  • Chapter 1: Stroke and Neuroprotection 1 – 21
    DEVELOPMENT OF NOVEL THERAPEUTICS FOR STROKE: PRECLINICAL INVESTIGATIONS OF OSTEOPONTIN AND 3-IODOTHYRONAMINE By Kristian Paul Doyle A DISSERTATION Presented to the Department of Molecular Microbiology & Immunology at the Oregon Health & Science University in partial fulfillment of the requirements for the degree of Doctor of Philosophy 1 CONTENTS List of Figures v List of Tables ix Acknowledgements x Preface xi Abstract xii List of Abbreviations xv Chapter 1: Stroke and Neuroprotection 1 – 21 1.1 Introduction 2 1.2 Brief History of Stroke 2 1.3 Stroke Pathophysiology 4 1.4 Neuroprotection 17 1.5 Ischemic Preconditioning 19 1.6 Research Goal 21 Chapter 2: Osteopontin 22-86 2.1 An Introduction to OPN 23 2.2 The Structure of OPN 23 2.3 OPN, Integrins and Survival Signaling 25 2.4 OPN and Ischemic Injury 27 2.5 Preclinical Development of OPN 33 2.6 Optimizing Delivery 33 2 2.7 Improving the Potency of OPN 36 2.8 Identifying the Regions of OPN required for Neuroprotection 36 2.9 Hypothesis 37 2.10 Research Design 38 2.11 OPN has neuroprotective capability in vivo and in vitro 40 2.12 The mechanism of neuroprotection by OPN 51 2.13 OPN can be delivered to the brain by intranasal administration 56 2.14 Enhancing the neuroprotective capability of OPN 60 2.15 Peptides based on the N and C terminal fragment of thrombin cleaved OPN are neuroprotective 65 2.16 The C terminal peptide requires phosphorylation to be neuroprotective while the N terminal peptide does not require phosphorylation 70 2.17 Dose response and time window of NT 124-153 71 2.18
    [Show full text]
  • Copyrighted Material
    Index Note: page numbers in italics refer to figures; those in bold to tables or boxes. abacavir 686 tolerability 536–537 children and adolescents 461 acamprosate vascular dementia 549 haematological 798, 805–807 alcohol dependence 397, 397, 402–403 see also donepezil; galantamine; hepatic impairment 636 eating disorders 669 rivastigmine HIV infection 680 re‐starting after non‐adherence 795 acetylcysteine (N‐acetylcysteine) learning disability 700 ACE inhibitors see angiotensin‐converting autism spectrum disorders 505 medication adherence and 788, 790 enzyme inhibitors obsessive compulsive disorder 364 Naranjo probability scale 811, 812 acetaldehyde 753 refractory schizophrenia 163 older people 525 acetaminophen, in dementia 564, 571 acetyl‐L‐carnitine 159 psychiatric see psychiatric adverse effects acetylcholinesterase (AChE) 529 activated partial thromboplastin time 805 renal impairment 647 acetylcholinesterase (AChE) acute intoxication see intoxication, acute see also teratogenicity inhibitors 529–543, 530–531 acute kidney injury 647 affective disorders adverse effects 537–538, 539 acutely disturbed behaviour 54–64 caffeine consumption 762 Alzheimer’s disease 529–543, 544, 576 intoxication with street drugs 56, 450 non‐psychotropics causing 808, atrial fibrillation 720 rapid tranquillisation 54–59 809, 810 clinical guidelines 544, 551, 551 acute mania see mania, acute stupor 107, 108, 109 combination therapy 536 addictions 385–457 see also bipolar disorder; depression; delirium 675 S‐adenosyl‐l‐methionine 275 mania dosing 535 ADHD
    [Show full text]
  • (12) United States Patent (10) Patent N0.: US 7,964,607 B2 Verhoest Et A1
    US007964607B2 (12) United States Patent (10) Patent N0.: US 7,964,607 B2 Verhoest et a1. (45) Date of Patent: Jun. 21, 2011 (54) PYRAZOLO[3,4-D]PYRIMIDINE FOREIGN PATENT DOCUMENTS COMPOUNDS EP 1460077 9/2004 WO 02085904 10/2002 (75) Inventors: Patrick Robert Verhoest, Old Lyme, CT WO 2004037176 5/2004 (US); Caroline ProulX-Lafrance, Ledyard, CT (US) OTHER PUBLICATIONS Wunder et a1, M01. PharmacoL, v01. 28, N0. 6, (2005), pp. 1776 (73) Assignee: P?zer Inc., New York, NY (U S) 1781. van der Staay et a1, Neuropharmacology, v01. 55 (2008), pp. 908 ( * ) Notice: Subject to any disclaimer, the term of this 918. patent is extended or adjusted under 35 USC 154(b) by 562 days. Primary Examiner * Susanna Moore (74) Attorney, Agent, or Firm * Jennifer A. Kispert; (21) Appl.No.: 12/118,062 Michael Herman (22) Filed: May 9, 2008 (57) ABSTRACT (65) Prior Publication Data The invention provides PDE9-inhibiting compounds of For US 2009/0030003 A1 Jan. 29, 2009 mula (I), Related US. Application Data (60) Provisional application No. 60/917,333, ?led on May 11, 2007. (51) Int. Cl. C07D 48 7/04 (2006.01) A61K 31/519 (2006.01) A61P 25/28 (2006.01) (52) US. Cl. ................................... .. 514/262.1; 544/262 (58) Field of Classi?cation Search ................ .. 544/262; 5 1 4/2 62 .1 See application ?le for complete search history. and pharmaceutically acceptable salts thereof, Wherein R, R1, (56) References Cited R2 and R3 are as de?ned herein. Pharmaceutical compositions containing the compounds of Formula I, and uses thereof in U.S.
    [Show full text]
  • Impact of Open Channel Blockers on the Surface Dynamics and Organization of NMDA Receptors Alexandra Fernandes
    Impact of open channel blockers on the surface dynamics and organization of NMDA receptors Alexandra Fernandes To cite this version: Alexandra Fernandes. Impact of open channel blockers on the surface dynamics and organization of NMDA receptors. Neurons and Cognition [q-bio.NC]. Université de Bordeaux, 2020. English. NNT : 2020BORD0181. tel-03177416 HAL Id: tel-03177416 https://tel.archives-ouvertes.fr/tel-03177416 Submitted on 23 Mar 2021 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. THÈSE PRÉSENTÉE POUR OBTENIR LE GRADE DE DOCTEUR DE L’UNIVERSITÉ DE BORDEAUX ÉCOLE DOCTORALE Sciences de la Vie et de la Santé SPÉCIALITÉ Neurosciences Par Alexandra FERNANDES Impact of open channel blockers on the surface dynamics and organization of NMDA receptors Sous la direction de Julien DUPUIS Soutenue le 10 Novembre 2020 Membres du jury : Mme SANS, Nathalie Directeur de recherche INSERM Président M. DE KONINCK, Paul Professeur, University of Laval Rapporteur Mme LÉVI, Sabine Directeur de recherche CNRS Rapporteur Mme CARVALHO, Ana Luísa Professeur, University of Coimbra Examinateur M. DUPUIS, Julien Chargé de recherche INSERM Directeur THÈSE PRÉSENTÉE POUR OBTENIR LE GRADE DE DOCTEUR DE L’UNIVERSITÉ DE BORDEAUX ÉCOLE DOCTORALE Sciences de la Vie et de la Santé SPÉCIALITÉ Neurosciences Par Alexandra FERNANDES Impact des bloqueurs de canal ouvert sur la dynamique et l’organisation de surface des récepteurs NMDA Sous la direction de Julien DUPUIS Soutenue le 10 Novembre 2020 Membres du jury : Mme SANS, Nathalie Directeur de recherche INSERM Président M.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Neu2000, an NR2B-Selective, Moderate NMDA Receptor
    Drug News & Perspectives 2010, 23(9): 549-556 THOMSON REUTERS LOOKING AHEAD Targeting both NMDA receptors and free NEU2000, AN NR2B-SELECTIVE, radicals may provide MODERATE NMDA RECEPTOR enhanced ANTAGONIST AND POTENT SPIN neuroprotection against TRAPPING MOLECULE FOR hypoxic-ischemic injury. STROKE confer substantial neuroprotection in ani- by Sung Ig Cho, Ui Jin Park, mal models of stroke have failed to show SUMMARY Jun-Mo Chung and Byoung Joo Gwag beneficial effects in clinical trials for stroke. Excess activation of ionotropic gluta- Free radicals mediate an additional route of mate receptors, primarily N-methyl-D- Stroke is a cerebrovascular injury caused by neuronal cell death after ischemia and aspartate (NMDA) receptors and free the interruption of blood flow to the brain reperfusion. Several antioxidants have radicals, evoke nerve cell death follow- due to thrombosis, embolic particles or advanced to clinical trials including edar- ing hypoxic-ischemic brain injury in var- blood vessel bursts. Stroke is the leading avone, a hydroxyl radical scavenger that has ious animal models. However, clinical cause of serious, long-term disability in shown beneficial effects in patients with trials in stroke patients using NMDA adults and the second leading cause of transient ischemia and which was approved receptor antagonists have failed to death in the U.S. and Europe (1). Rates of as a neuroprotective drug in Japan and show efficacy primarily due to the limit- stroke mortality and burden are more China. ed therapeutic time window for neuro- affected in low-income countries including protection and a narrow therapeutic NMDA receptor antagonists and antioxi- eastern Europe, northern Asia and central index.
    [Show full text]
  • Files\OLK36\Copyright - Thesis.Doc
    REFERENCE ONLY UNIVERSITY OF LONDON THESIS Degree y ear * 1 0 0 ^ Name of Author COPYRIGHT This is a thesis accepted for a Higher Degree of the University of London. It is an unpublished typescript and the copyright is held by the author. All persons consulting the thesis must read and abide by the Copyright Declaration below. COPYRIGHT DECLARATION I recognise that the copyright of the above-described thesis rests with the author and that no quotation from it or information derived from it may be published without the prior written consent of the author. LOAN Theses may not be lent to individuals, but the University Library may lend a copy to approved libraries within the United Kingdom, for consultation solely on the premises of those libraries. Application should be made to: The Theses Section, University of London Library, Senate House, Malet Street, London WC1E 7HU. REPRODUCTION University of London theses may not be reproduced without explicit written permission from the University of London Library. Enquiries should be addressed to the Theses Section of the Library. Regulations concerning reproduction vary according to the date of acceptance of the thesis and are listed below as guidelines. A. Before 1962. Permission granted only upon the prior written consent of the author. (The University Library will provide addresses where possible). B. 1962- 1974. In many cases the author has agreed to permit copying upon completion of a Copyright Declaration. C. 1975 - 1988. Most theses may be copied upon completion of a Copyright Declaration. D. 1989 onwards. Most theses may be copied. This thesis comes within category D.
    [Show full text]
  • Clinical Review Huntington's Disease
    CLINICAL REVIEW For the full versions of these articles see bmj.com Huntington’s disease Marianne J U Novak,1 2 Sarah J Tabrizi1 3 1National Hospital for Neurology Huntington’s disease is a devastating inherited and Neurosurgery, London neurodegenerative disease characterised by progressive motor, WC1N 3BG cognitive, and psychiatric symptoms. Patients may present 2Wellcome Trust Centre for Neuroimaging, UCL Institute of with any of these symptoms, and familiarity with the pheno- Neurology, London WC1N 3BG type is therefore important. Chorea and loss of balance are 3Department of Neurodegenerative early symptoms that patients notice, although families often Disease, UCL Institute of Neurology notice cognitive or personality changes before this. Correspondence to: S Tabrizi [email protected] The disease occurs in all racial groups but is most common in people of northern European origin. Its prevalence in the Cite this as: BMJ 2010;340:c3109 Western hemisphere is 7-10/100 000.w1 The mean age of onset doi: 10.1136/bmj.c3109 of symptoms is 40 years, but juvenile onset (<20 years) and older onset (>70 years) forms are well recognised. The Hunt- ington’s Disease Association (HDA) has records of 6161 adults with symptomatic Huntington’s disease and 541 children with juvenile Huntington’s disease (in England and Wales) at the Fig 1 | Statistical parametric map showing grey matter volume loss in patient groups compared with controls. Pre-A and time of writing. This is a conservative estimate of prevalence pre-B are premanifest Huntington’s disease gene carriers with because it includes only those people in contact with the HDA, estimated time to clinical disease onset greater than and less and it suggests that the true prevalence of the disease is higher than 10.8 years, respectively.
    [Show full text]
  • 2009 Nhamcs Micro-Data File Documentation Page 1
    2009 NHAMCS MICRO-DATA FILE DOCUMENTATION PAGE 1 ABSTRACT This material provides documentation for users of the public use micro-data files of the 2009 National Hospital Ambulatory Medical Care Survey (NHAMCS). NHAMCS is a national probability sample survey of visits to hospital outpatient and emergency departments, conducted by the National Center for Health Statistics, Centers for Disease Control and Prevention. The survey is a component of the National Health Care Surveys, which measure health care utilization across a variety of health care providers. There are two micro-data files produced from NHAMCS, one for outpatient department records and one for emergency department records. Section I of this documentation, “Description of the National Hospital Ambulatory Medical Care Survey,” includes information on the scope of the survey, the sample, field activities, data collection procedures, medical coding procedures, and population estimates. Section II provides detailed descriptions of the contents of each file’s data record by location. Section III contains marginal data for selected items on each file. The appendixes contain sampling errors, instructions and definitions for completing the Patient Record forms, and lists of codes used in the survey. PAGE 2 2009 NHAMCS MICRO-DATA FILE DOCUMENTATION SUMMARY OF CHANGES FOR 2009 The 2009 NHAMCS Emergency Department and Outpatient Department public use micro-data files are, for the most part, similar to the 2008 files, but there are some important changes. These are described in more detail below and reflect changes to the survey instrument, the Patient Record form. Emergency Departments 1. New or Modified Items a. In item 1, Patient Information, there is a new checkbox item “Arrival by Ambulance.” This replaces the 2008 item, “Mode of Arrival.” b.
    [Show full text]